AstraZeneca FDA delay affects camizestrant approval for breast cancer treatment, following inconclusive evidence from advisory panel.
Author: PharmaSignal News Desk
Lilly vaccine acquisitions include Curevo, LimmaTech, and Vaccine Co., totaling $4 billion, to enhance its infectious disease portfolio.
BioMarin Voxzogo trial demonstrates positive outcomes, potentially expanding its use amid increased competition.
Sun Pharma acquisition highlights India’s global ambitions, but infrastructure and policy gaps remain challenges.
Regenxbio Duchenne gene therapy aims for FDA approval despite side effects.
• Regenxbio seeks FDA approval for Duchenne gene therapy.
• Therapy targets rare disease affecting 1 in 3,500 boys.
• CEO optimistic despite two serious side effects.
Assertio buyout bid accepted, offering a 31% premium over initial proposal, impacting the US market.
Arvinas Pfizer Rigel deal secures future of Veppanu, a novel breast cancer drug, ending months of uncertainty.
Bristol Myers Hengrui alliance involves 13 drugs, marking a significant step in global pharmaceutical collaboration.
GSK Sino hepatitis B deal aims to broaden access to bepirovirsen, enhancing treatment options for millions in China.
Pierre Fabre FDA Reevaluation marks a strategic alignment for a twice-rejected cell therapy, potentially impacting the regulatory landscape.